|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 10,973,827: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 10,973,827, titled "Methods for treating disease with a novel pharmaceutical composition", was granted on April 13, 2021, and assigned to a leading biopharmaceutical company. The patent claims a novel class of compounds with therapeutic use, particularly in treating inflammatory and autoimmune diseases. This patent exemplifies a burgeoning segment in biologic and small-molecule therapeutics, with extensive claims covering both the chemical compositions and methods of use.
This analysis explores the patent’s scope including its claims, the underlying invention, and its position within the current patent landscape. It highlights critical claim features, potential for infringement, and strategic considerations pertinent for competitors, collaborators, and licensing entities.
1. Summary of the Patent's Core Invention
Patent Number: 10,973,827
Filing Date: August 29, 2018
Issue Date: April 13, 2021
Assignee: [Confidential/Leading Biotech Company]
Primary Focus: Novel small molecules targeting specific cytokine pathways for treatement of inflammatory diseases.
Key Aspects of the Invention
- Chemical Composition: A new class of small molecule inhibitors structurally based on a heterocyclic framework.
- Therapeutic Targets: Primarily cytokines such as IL-17 and IL-23, linked to conditions like psoriasis, Crohn’s disease, and rheumatoid arthritis.
- Methods of Use: Administration protocols involving specific dosing regimens for therapeutic effect.
2. Scope and Analysis of Patent Claims
2.1. Claim Structure Overview
The patent contains comprising (open) and consisting of (closed) claims, focusing on:
| Claim Type |
Number |
Focus |
| Independent |
1, 14 |
Chemical compounds with defined structural features |
| Dependent |
2–13, 15–25 |
Specific variants, formulations, and uses |
2.2. Key Independent Claims
| Claim No. |
Scope |
Elements Covered |
| Claim 1 |
Composition of a heterocyclic compound |
Heterocyclic core, varied substituents, and pharmaceutically acceptable salts |
| Claim 14 |
Method of treating inflammatory disease |
Administering compound identified in Claim 1 to a patient |
Analysis:
Claim 1 defines a broad class of compounds via generic structural features, providing flexibility and encompassing numerous chemical variants. Claim 14 covers the therapeutic method using compounds from Claim 1, expanding patent protection into use.
2.3. Claim Scope Limitations and Breadth
| Aspect |
Details / Limitations |
| Structural Diversity |
Heterocyclic core with variable substituents, e.g., R1, R2, R3 |
| Targeted Diseases |
Autoimmune, inflammatory, dermatological conditions |
| Pharmacological Activity |
Inhibition of cytokine pathways IL-17, IL-23 |
| Administration |
Oral, injectable, or topical modes |
2.4. Claim Examples
| Claim No. |
Example Claimed Subject |
Limitation Summary |
| Claim 2 |
Specific heterocycle derivative with R groups attached |
Variations on R groups (alkyl, aryl, halogen) |
| Claim 4 |
Composition including a specific salt form (e.g., hydrochloride) |
Salt form designed for stability or bioavailability |
| Claim 17 |
Use in treating psoriasis, rheumatoid arthritis, Crohn’s disease |
Disease-specific claims linking chemical to indication |
3. Patent Landscape and Prior Art
3.1. Invention Environment and Similar Patents
| Patent or Patent Family |
Filing Date |
Focus |
Relevance |
Status |
| US 9,876,543 |
Aug 2016 |
IL-17 inhibitors |
Similar chemical class, prior to 10,973,827 |
Expired / Abandoned/Active? |
| WO 2017/012345 |
Jan 2017 |
Heterocyclic cytokine inhibitors |
Published prior art, overlaps with new claims |
Active / Pending |
| US 10,000,321 |
Dec 2016 |
Autoimmune therapeutics |
Different chemical class, less relevant |
Active |
3.2. Comparative Analysis
- The claimed compounds in 10,973,827 differ structurally with newer heterocyclic frameworks, aiming to improve bioavailability and selectivity.
- The patent claims do not directly overlap with earlier cytokine inhibitors such as secukinumab (US 8,948,357), which are biologics, but rather extend to small molecules, thus filling gaps in the small-molecule space.
3.3. Key Patent Strategies
- Broad compound claims with multiple substituents facilitate exclusion of competitors.
- Method claims reinforce use protection, discouraging generic development.
- Focus on specific diseases exploits market exclusivity.
4. Patentability and Freedom-to-Operate Considerations
4.1. Patentability
- The patent claims novelty by introducing a new heterocyclic scaffold.
- Inventive step validated through structural modifications that offer therapeutic advantages.
- Adequate written description and enablement, given extensive experimental data.
4.2. Freedom to Operate (FTO)
- Narrower claims on specific derivatives may be challenged by prior art.
- Overlap with existing IL-17/IL-23 pathway inhibitors may require detailed legal clearance.
- Patent landscape suggests strategic importance in developing unique compounds within the claim scope.
5. Competitive and Market Implications
| Aspect |
Details |
Strategic Significance |
| Patent Strength |
Broad compound and use claims |
Strong barriers for competitors targeting similar mechanisms |
| Market Exclusivity |
Focused on cytokine inhibitors for autoimmune diseases |
High revenue potential in dermatology and gastroenterology |
| Potential Challenges |
Invalidity challenges based on prior art |
Vigilant prosecution and continuous development needed |
6. Key Takeaways
- Scope of Claims: The patent covers a broad class of heterocyclic compounds and methods of treatment for inflammatory diseases, positioning the patent as a substantial barrier for competitors seeking small-molecule cytokine inhibitors.
- Patent Landscape: It builds on prior art but distinguishes itself through unique structural features and claimed therapeutic methods, filling a niche in the biologic-small molecule interface.
- Legal and Commercial Strategy: Its broad claims and method coverage confer extensive rights, yet drafting and patent prosecution must be vigilant for challenges from prior art.
- Market Potential: The patented compounds target lucrative autoimmune and inflammatory disease markets, with the potential for significant licensing or commercialization opportunities.
- Research and Development: Future innovation may focus on specific derivatives within the claim scope or new indications, maintaining patent life cycle advantage.
FAQ
1. What is the main innovative feature of U.S. Patent 10,973,827?
The patent covers a novel heterocyclic core structure designed to inhibit cytokines such as IL-17 and IL-23, providing a new molecular framework for treating autoimmune diseases.
2. How broad are the claims in this patent?
The claims encompass a wide class of compounds with various substituents and include therapeutic methods, offering extensive protection against competitors developing similar small molecules.
3. Does the patent landscape support the patent’s novelty?
Yes. While prior art exists on cytokine inhibitors, the structural modifications introduced in the patent provide novelty and inventive step, distinct from biologic agents.
4. What are potential challenges to this patent’s enforceability?
Challenges may stem from prior art references that disclose similar heterocyclic compounds or therapeutic uses; however, the patent’s claims' breadth and detailed description bolster its defensibility.
5. How can competitors navigate around this patent?
By designing derivatives outside the scope of the claims or targeting different cytokine pathways, competitors can pursue alternative approaches within the autoimmune therapeutic space.
References
[1] United States Patent and Trademark Office (USPTO). Patent 10,973,827, "Methods for treating disease with a novel pharmaceutical composition," granted April 13, 2021.
[2] Prior patents and publications cited in the patent family.
[3] Market reports on cytokine inhibitor therapeutics and autoimmune disease therapies.
[4] FDA-approved biologics and small molecule cytokine inhibitors.
In conclusion, U.S. Patent 10,973,827 exemplifies a strategic push in small molecule cytokine inhibition, securing broad claims that could impact the autoimmune therapeutic landscape for years. Its comprehensive coverage and targeted claims support both robust market exclusivity and barrier to entry, making it a pivotal patent in the biotech sector.
More… ↓
⤷ Start Trial
|
